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The majority of T-cell clones derived from a donor who experienced dengue illness following receipt of a live
experimental dengue virus type 3 (DEN3) vaccine cross-reacted with all four serotypes of dengue virus, but
some were serotype specific or only partially cross-reactive. The nonstructural protein, NS3, was immuno-
dominant in the CD41 T-cell response of this donor. The epitopes of four NS3-specific T-cell clones were
analyzed. JK15 and JK13 recognized only DEN3 NS3, while JK44 recognized DEN1, DEN2, and DEN3 NS3 and
JK5 recognized DEN1, DEN3, and West Nile virus NS3. The epitopes recognized by these clones on the DEN3
NS3 protein were localized with recombinant vaccinia viruses expressing truncated regions of the NS3 gene,
and then the minimal recognition sequence was mapped with synthetic peptides. Amino acids critical for T-cell
recognition were assessed by using peptides with amino acid substitutions. One of the serotype-specific clones
(JK13) and the subcomplex- and flavivirus-cross-reactive clone (JK5) recognized the same core epitope,
WITDFVGKTVW. The amino acid at the sixth position of this epitope is critical for recognition by both clones.
Sequence analysis of the T-cell receptors of these two clones showed that they utilize different Vb chains. The
core epitopes for the four HLA-DR15-restricted CD41 CTL clones studied do not contain motifs similar to
those proposed by previous studies on endogenous peptides eluted from HLA-DR15 molecules. However, the
majority of these dengue virus NS3 core epitopes have a positive amino acid (K or R) at position 8 or 9. Our
results indicate that a single epitope can induce T cells with different virus specificities despite the restriction
of these T cells by the same HLA-DR15 allele. This finding suggests a previously unappreciated level of
complexity for interactions between human T-cell receptors and viral epitopes with very similar sequences on
infected cells.
Dengue viruses are members of the family Flaviviridae and
are transmitted to humans predominantly by Aedes aegypti and
Aedes albopictus mosquitoes (30). Molecular epidemiologic
studies have shown that the dengue viruses in forest cycles are
distinct from the viruses circulating between humans and mos-
quitoes in urban transmission cycles (32). Although sporadic
pandemics of dengue fever are known to have occurred at
intervals of up to 30 years over the past 200 years, the more
severe form of disease, dengue hemorrhagic fever (DHF), was
recognized only after multiple dengue virus serotypes had es-
tablished overlapping hyperendemic transmission patterns in
urban areas around the Pacific following World War II (30).
Since then, endemic transmission cycles with multiple sero-
types of dengue virus have been established in regions of Asia,
Africa, and the Americas, and dengue virus has now become
the leading cause of arthropod-borne virus disease in humans
(11, 30). The number of annual dengue fever cases worldwide
is estimated to be more than 100 million, with 250,000 reported
cases of DHF. The true incidence of both diseases is estimated
to be severalfold higher (30). Patients with DHF first show
symptoms typical of dengue fever but then rapidly develop
thrombocytopenia, diffuse capillary leakage, hemoconcentra-
tion, and hypotension. In the most severe form of the disease,
dengue shock syndrome, the pulse pressure narrows and cir-
culatory failure can occur. Supportive treatment has reduced
case fatality rates from 20% to 1% (30).
Dengue viruses contain an 11-kb single-stranded RNA ge-
nome of positive polarity and are divided into four antigeni-
cally distinct serotypes, designated types 1, 2, 3, and 4 (7).
Comparison of the genomic sequences of different dengue
virus serotypes revealed a 65 to 75% nucleotide and a 67 to
75% amino acid homology (10). Dengue viruses within a se-
rotype vary from each other by about 10% at the nucleotide
level and by about 4% at the amino acid level (32, 36). Dengue
viruses predominantly infect mononuclear phagocytes (13).
Children are the most susceptible hosts for DHF. In some
areas of the world, DHF is now the third or fourth most
frequent cause of hospitalization of children (14). DHF is most
often associated with a secondary dengue infection caused by a
dengue virus serotype different from that causing the primary
infection. Serotype-cross-reactive antibodies induced during
primary dengue virus infection are rapidly produced during
secondary infection and form infectious immune complexes
with virus. These virus-antibody complexes can efficiently in-
fect monocytes via the Fc receptor, a phenomenon termed
immune enhancement, which has been hypothesized to cause
an increase in the number of infected cells and the yield of
virus (12, 13). Marked activation of both CD41 and CD81
dengue virus serotype-cross-reactive cytotoxic T cells occurs in
humans infected with dengue virus (19, 22–25). Elevated levels
of soluble CD41 were found in children with dengue infection
and were highest in children with DHF (23). The levels of
soluble CD41 are indicative of the level of CD41 T-cell acti-
vation.
The host- and virus-specific factors that determine why a















secondary dengue virus infection in one individual causes no
symptoms or dengue fever but DHF develops in another indi-
vidual are currently not well understood. Also, to date, there is
no animal model for DHF. Both serotype-specific and sero-
type-cross-reactive CD41 CD82 and CD42 CD81 dengue vi-
rus-specific memory T cells have been obtained from human
donors immunized with a single-serotype, live, attenuated, ex-
perimental dengue virus vaccine (4, 19). In bulk culture, these
T cells respond to stimulation by each of the four dengue virus
serotypes but always show the highest response to the homol-
ogous serotype. Similar results were also obtained with murine
memory T cells derived from animals immunized with a single
serotype of dengue virus (33). For about 50% of the human
donors tested thus far, the nonstructural protein NS3 is the
immunodominant dengue virus protein, while the viral enve-
lope protein is immunodominant for the others (21). The NS3
protein contains an N-terminal protease domain and a C-
terminal helicase domain (5, 7).
The T-cell clones used in this study were isolated from a
donor who had been immunized with yellow fever virus (YFV)
vaccine and then with an experimental dengue virus type 3
(DEN3) vaccine. Most of the T-cell clones isolated from this
donor were dengue virus serotype cross-reactive (19). To iden-
tify the amino acids involved in restricted recognition by sero-
type-specific and subcomplex-cross-reactive T-cell clones, two
DEN3-specific, one dengue virus subcomplex-cross-reactive,
and one dengue virus subcomplex- and flavivirus-cross-reactive
clone were selected for epitope mapping. Amino acid se-
quences involved in recognition by these four T-cell clones
were determined by using vaccinia virus (VV) recombinants
and overlapping synthetic peptides.
MATERIALS AND METHODS
Cells. Vero cells were obtained from the American Type Culture Collection
and used to grow the four serotypes of dengue virus. CV-1 and 143 B cells were
provided by Paul Rota, Centers for Disease Control and Prevention, and were
used for recombinant VV production. These three cell lines were cultured in
minimal essential medium containing 5 or 10% fetal calf serum. A lymphoblas-
toid cell line (B cell) was established by Epstein-Barr virus transformation of
homologous peripheral blood mononuclear cells obtained from the donor and
cultured in RPMI containing 10% fetal calf serum as described previously (19).
Establishment of dengue virus-specific human T-cell clones. The details of the
procedures used to establish the four T-cell clones described in this report were
previously described in detail (19, 24). Peripheral blood mononuclear cells (4 3
105) were cultured for 7 days with dengue virus antigen at a final dilution of 1:30
in 0.2 ml of RPMI containing 10% human AB serum in 96-well round-bottom
plates. On day 7, blast cells were enriched by Ficoll-Hypaque density gradient
centrifugation. The JK5, JK13, and JK15 clones were established by culturing
blast cells at a concentration of three cells per well in the presence of g-irradiated
autologous peripheral blood mononuclear cells (105) in 0.2 ml of RPMI con-
taining 10% human AB serum, 10% interleukin-2, and dengue virus antigen at a
final concentration of 1:30. The JK44 clone was established by using 10 cells per
well. The JK5, JK13, and JK15 clones were established in the presence of DEN3
antigen, while the JK44 clone was established with DEN2 antigen. PCR analysis
of the Vb chains of the T-cell receptor (TCR) detected only a single Vb band for
each of these four clones (data not shown). In addition, a single Va band was
detected for two of the clones, JK5 and JK15. These data indicate that each of
these four T-cell lines is a clone.
Viruses. DEN1 (Hawaii strain) and DEN2 (New Guinea C strain) were ob-
tained from Walter E. Brandt, Walter Reed Army Institute of Research, Wash-
ington, D.C. DEN3 (CH 53489 strain) was provided by Bruce L. Innis, Armed
Forces Research Institute of Medical Science, Bangkok, Thailand, and DEN4
(814669 strain) was provided by Jack McCown, Walter Reed Army Institute of
Research. YFV (17D strain) was supplied by Jacob J. Schlesinger, University of
Rochester School of Medicine and Dentistry. West Nile virus (WNV) was ob-
tained from J. S. Porterfield. VV (Wyeth strain) was provided by Paul Rota.
Stocks of dengue virus and YFV were propagated in C6/36 cells. Stocks of WNV
and VV were propagated in BHK and CV-1 cells, respectively.
Preparation of dengue virus antigens. Dengue virus antigens, YFV antigen,
and WNV antigen were prepared from infected Vero cells as described previ-
ously (19), using virus-infected cytoplasmic supernatant obtained from the cell
extract by centrifugation at 2,000 3 g for 10 min. The control antigen was
prepared in the same manner, using uninfected Vero cells. All antigen prepara-
tions were in a volume of 15 ml and were from 15 T-75 flasks (Corning) of
confluent Vero cells.
Construction of VV recombinants. VV recombinants expressing DEN2 NS3 or
DEN3 NS3 were generated as described previously (28). Briefly, DEN2 and
DEN3 genomic RNAs were extracted from virions partially purified by sedimen-
tation through a 5, 10, and 20% discontinuous glycerol gradient made with TNE
buffer (50 mM Tris-HCl [pH 7.2], 100 mM NaCl, 1 mM EDTA). The NS3 genes
of DEN2 and DEN3 were amplified from their respective genomic RNAs by
reverse transcription-PCR, using forward and reverse 20-mer primers located at
the 59 and 39 ends of the gene. The 59 primer contained a BamHI site and an
in-frame AUG start codon immediately preceding the NS3 N-terminal coding
sequence, while the 39 primer contained a UAA stop codon followed by a
HindIII site. Neither a BamHI site nor a HindIII site is present in the NS3 gene.
The PCR cycle used was 948C for 1 min, 428C for 20 s, and 728C for 3 min for a
total of 30 cycles. PCR products were cloned into the VV transfer plasmid
pKG19 at the BamHI andHindIII restriction sites. The junction sequences of the
recombinant plasmids produced were confirmed by dideoxy sequencing (35).
Recombinant plasmid pKG19-D3NS3 (5 mg) or pKG19-D2NS3 (5 mg) and
wild-type VV DNA (1 mg) were transfected into CV-1 cells in the presence of
Lipofectin (25 mg; Bethesda Research Laboratories). At the time of transfection,
CV-1 cells were 75% confluent and had been infected with VV for 2 h at a
multiplicity of infection of 0.01. VV recombinants were plaque purified on 143 B
cells (thymidine kinase negative) in the presence of bromodeoxyuridine (0.3
mg/ml), amplified in CV-1 cells in 24-well plates, and resuspended in 300 ml of
PBS-M buffer (phosphate-buffered saline supplemented with 0.1 M MgSO4).
The virus sample (10 ml) was diluted 10-fold with buffer containing 10 mM
Tris-HCl (pH 8.5), 1% Nonidet P-40, and 2 mg of protease K per ml and
incubated at 658C for 2 h. After being heated at 1008C for 10 min to inactivate
the protease, cell lysates (5 ml for each) were used as templates for PCR to
confirm the presence of the insert in the recombinant. The forward and reverse
primers were located at the 59 and 39 ends of the inserted gene. Recombinant
viruses VVD2-NS3 and VVD3-NS3 were plaque purified two additional times in
the presence of bromodeoxyuridine before further use.
VV recombinants expressing various N-terminally or C-terminally deleted
versions of DEN3 NS3 were constructed by a similar procedure. Figure 1 shows
the truncation sites. The various C-terminally deleted fragments of the DEN3
NS3 gene were produced by PCR amplification from pKG19-D3NS3 plasmid
DNA, using the genomic sense DEN3 NS3 gene 59 primer described above for
amplifying the entire DEN3 NS3 gene and different antisense 39 primers. The 39
primers contained a stop codon and a HindIII site. Two N-terminally deleted
NS3 fragments were also generated by PCR, using the genomic antisense DEN3
NS3 gene 39 primer described above for amplifying the entire DEN3 NS3 gene
and different genomic sense primers containing a BamHI restriction site and an
AUG codon. All of the primers were 18 to 21 nucleotides in length. PCR
amplification of the truncated NS3 fragments was performed under the condi-
tions used for the complete NS3 gene except that the extension time was reduced
by 1 or 2 min as the length of the template decreased.
Synthetic peptides and oligonucleotides. Peptides were synthesized with an
automated model 431A peptide synthesizer (Applied Biosystems). The N-termi-
nal 9-fluorenylmethoxycarbonyl group was removed from peptides on the ma-
chine. Peptides were deprotected and cleaved from the resin according to the
procedure suggested by the manufacturer. Oligonucleotides were synthesized on
a model 384 DNA synthesizer (Applied Biosystems).
FIG. 1. Schematic representation of the truncated NS3 proteins expressed by recombinant VV. Bent arrows on the NS3 gene represent the truncation sites. D3-C1
and D3-C2 are C-terminal fragments; all others are N-terminal fragments.













Cytotoxic T-lymphocyte (CTL) assay. Target B-lymphoblastoid cells were in-
fected with recombinant VV or pulsed with viral antigen as described previously
(4, 19). A total of 106 target cells were infected with recombinant or wild-type VV
at a multiplicity of infection of 10 to 20 or incubated with virus antigen diluted
1:80. After overnight incubation, target cells were labeled with 500 mCi of
Na251CrO4 (Dupont) at 378C for 45 min and washed three times with RPMI–
10% fetal calf serum.
The procedures used for peptide pulsation were similar to those used for viral
antigen described above (20). Cells were labeled with 51Cr, and then 103 cells in
0.1 ml were pulsed with 50 ml of peptide at a concentration of 25, 2.5, 0.25, 0.025,
or 0.0025 mg/ml for 30 min at 378C.
Labeled target cells (0.1 ml) were added to each well of a round-bottom
microtiter plate (Falcon Plastic) at a concentration of 104 cells per ml. CTLs were
then added to each well in various concentrations to give different effector/target
ratios. CTLs were added in a volume of 0.1 ml for viral antigen and VV exper-
iments and in a volume of 50 ml for peptide experiments. The CTL assay was
carried out for 4 h at 378C, and the supernatant fluids were collected from each
well with a Titertek harvester (Skatron Instruments, Lier, Norway). Released
51Cr was measured with a gamma counter, and the percentage of specific 51Cr
release was calculated with the following formula: 100 3 (cpm experimental
release 2 cpm spontaneous release)/[cpm maximal release (detergent lysis) 2
cpm spontaneous release]. Background levels of spontaneous 51Cr release from
labeled target cells were usually less than 25%.
Determination of the HLA restriction patterns of the T-cell clones. Monoclo-
nal antibody (MAb) B7/21.7, which detects HLA-DP, and MAb S3/4, which
detects HLA-DQ, were kindly provided by Nancy Reinsmoen, University of
Minnesota. MAb OKIa1 was purchased from Ortho Diagnostic Systems, Inc.,
Raritan, N.J. To analyze the HLA restriction pattern of JK44, 0.05 ml of a 1:20
dilution of MAb was added to 51Cr-labeled target cells, and cells were pulsed
with peptide 44b added to a final concentration of 2.5 mg/ml. These cells were
then used in the CTL assay (20).
In the second method used for HLA typing, autologous target B-lymphoblas-
toid cells were replaced with 3107, 3161, 9038, MS, or VA-9 cells in the cyto-
toxicity assay. Autologous B-lymphoblastoid cells and the allogeneic target cells,
MS and VA-9, had been previously HLA typed in the University of Massachu-
setts Medical Center Tissue Typing Laboratory. The other cell lines were pur-
chased from the National Institute of General Medical Sciences Human Genetic
Mutant Cell Repository (Camden, N.J.). Peptide 13-5d (0.25 mg/ml) was used to
coat target cells for HLA typing studies with both the JK13 and JK5 clones.
Peptides 15a (0.25 mg/ml) and 44b (2.5 mg/ml) were used for studies of the JK15
and JK44 clones, respectively.
Sequencing of DEN1 (Hawaii strain) within the JK5 recognition region. Su-
pernatant from DEN1 (Hawaii strain)-infected C6/36 cells was collected at 8
days after infection at a multiplicity of infection of 0.1. Virus was pelleted
through a discontinuous glycerol gradient, and viral RNA was extracted as
described above. Reverse transcription-PCR was performed with 18-mer primers
to amplify the region located between nucleotides 936 and 1165 of the DEN1
NS3 gene (10). The PCR cycle was 948C for 1 min, 428C for 20 s, and 728C for
2 min. A total of 30 cycles were run. The resulting PCR product was gel purified,
cloned into the pCRII vector (Invitrogen, Inc.), and sequenced.
Determination of Vb chain usage in the TCR. Total cytoplasmic RNA was
extracted from 5 3 105 cells by the acid guanidinium-phenol-chloroform method
(9). The RNA was treated with DNase I containing RNA Guard (Pharmacia
Biotec, Inc.). First-strand cDNA was synthesized from this RNA by using ran-
dom hexamers (Pharmacia Biotec) as primers and a Moloney murine leukemia
virus reverse transcriptase (Gibco-BRL Life Technologies, Inc.). PCR was then
performed with 1 of 26 59 primers located in the variable region of the b chain
and a 39 primer located in the constant region of the b chain. The 39 primer was
end labeled with [g-32P]ATP by using T4 polynucleotide kinase (Promega Corp.)
and purified on a Chroma Spin-10 column (Clontech Laboratories, Inc.). La-
beled primer (105 cpm) was added to each PCR mixture. The thermal cycle was
948C for 1 min, 558C for 1 min, and 728C for 1 min. A total of 26 cycles were
carried out. In the first cycle, a longer denaturation time (1.5 min) was used. PCR
products were electrophoresed on a 5% polyacrylamide gel. Radioactivity in
each PCR fragment was quantitated with a Betascope (Betagen).
Both strands of the PCR products were sequenced by using a double-stranded
DNA cycle sequencing system (Gibco-BRL Life Technologies) and 32P-labeled
primers.
RESULTS
Virus specificities of the T-cell clones. CD41 CD82 T-cell
clones were established from a donor previously immunized
with YFV vaccine and then with a live, attenuated, experimen-
tal DEN3 vaccine (19, 25). To analyze the virus specificities of
four of these clones, antigens from the four dengue virus se-
rotypes, YFV, or WNV were incubated with autologous Ep-
stein-Barr virus-transformed B-lymphoblastoid cells, and the
T-cell clones were examined for the ability to lyse the antigen-
pulsed target cells (Table 1). The JK13 and JK15 T-cell clones
lysed target cells pulsed with DEN3 virus antigen but did not
lyse target cells pulsed with DEN1, -2, or -4, YFV, or WNV
antigen. Therefore, JK13 and JK15 are DEN3-specific clones.
JK5 lysed target cells pulsed with DEN1 or -3 or WNV
antigen but did not lyse target cells pulsed with DEN2 or -4 or
YFV antigen. Therefore, JK5 is dengue virus subcomplex and
flavivirus subcomplex specific. This pattern of virus cross-reac-
tivity had not been observed in previous studies of human
dengue virus-specific T-cell clones (19). Repeated analysis of
the virus specificity of the JK5 clone consistently confirmed the
results in Table 1. The JK44 clone lysed target cells coated with
DEN1, -2, or -3 antigen but did not lyse target cells coated with
DEN4, YFV, or WNV antigen. This result is consistent with
previous data (19) indicating that JK44 is dengue serotype
subcomplex specific.
Recognition of VV-expressed dengue NS3 protein. As de-
scribed previously (19), most of the analyzed dengue virus-
cross-reactive JK T-cell clones, including JK44, recognize the
dengue virus NS3 protein. T-cell clone reactivity was detected
by using an available DEN4 NS3 protein expressed by VV or
an NS3 protein isolated from DEN3-infected cells (19). To
determine whether the new clones, JK5, JK13, and JK15, rec-
ognized the NS3 protein, we prepared two additional VV re-
combinants, VVD2-NS3 and VVD3-NS3, which expressed
DEN2 NS3 and DEN3 NS3, respectively, and used these con-
structs to infect target cells for cytotoxicity assays. All four of
the T-cell clones recognized NS3. Three of the clones, JK15,
JK13, and JK5, recognized target cells infected with VVD3-
NS3 but did not recognize target cells infected with VVD2-
NS3 or VV. JK44 recognized target cells infected with either
VVD2-NS3 or VVD3-NS3 (data not shown). None of the
clones recognized target cells infected with nonrecombinant
VV. The virus specificities detected with antigen expressed by
VV were consistent with those observed with virus-infected cell
extracts (Table 1).
Mapping the T-cell epitopes by using truncated DEN3 NS3
peptides expressed by VV recombinants. VV was used to ex-
press various terminally truncated fragments of NS3. The NS3
gene was truncated at six positions to produce five N-terminal
and one C-terminal NS3 fragments. VV recombinants express-
ing each of these truncated fragments were generated and
designated according to the order in which they were pro-
duced. The VV recombinants were used to infect target B cells,
which in turn were used to examine the cytotoxic activity of
each T-cell clone. We then made seven additional VV recom-
binants which expressed NS3 fragments that were truncated
within the recognition regions for each clone identified with
the first set of NS3 fragments (Fig. 1).
TABLE 1. Recognition of virus antigens by four CD41 CD82
T-cell clones
Clone
% Specific 51Cr releasea for target cells with:
DEN1 DEN2 DEN3 DEN4 YFV WNV Controlantigen
No
antigen
JK15 0 0 51 0 0 0 0 0
JK13 1 1 32 0 1 1 2 2
JK5 41 1 85 2 0 41 1 2
JK44 29 50 59 1 0 0 4 0
a Vero cell lysates infected with one of the four serotypes of dengue virus,
YFV, or WNV were used as virus antigens to coat target B cells for CTL assays.
An uninfected Vero cell lysate was used as the control antigen. Values repre-
senting significant levels of lysis are underlined. The CTL assay time was 4 h, and
the effector/target ratios were 20 for JK15, 11 for JK13, and 10 for JK5 and JK44.













JK15 lysed target cells infected with the positive control
VVD3-NS3, VVD3-2, or VVD3-3 but not with VVD3-1,
VVD3-5, or the wild-type VV negative control (Table 2). HLA
class II core epitope sequences usually contain 9 to 12 amino
acids. If the D3-5 truncation was made within the core se-
quence, JK15 would not be able to recognize the truncated
fragment. Therefore, the possible recognition region for JK15
was extended by 12 amino acids at the N-terminal end of the
D3-5 truncation point. The JK15 recognition region in NS3
was thus localized between amino acids 234 and 283.
JK44 lysed target cells infected with VVD3-NS3, VVD3-1,
VVD3-2, VVD3-3, or VVD3-5 but did not lyse target cells
infected with VVD3-4, VVD3-7, VVD3-9, VVD3-10, or
VVD3-C-1 (Table 2). Thus, the epitope recognized by JK44
was located between amino acids 194 and 214.
JK13 lysed target cells infected with VVD3-NS3, VVD3-2,
or VVD3-6 but not with VVD3-1, VVD3-3, VVD3-5,
VVD3-8, VVD3-11, VVD3-C1, or VV (Table 2). Similarly,
JK5 lysed target cells infected with VVD3-NS3, VVD3-2, or
VVD3-6 but did not lyse target cells infected with VVD3-3,
VVD3-5, VVD3-8, VVD3-11, VVD3-C1, or VVD3-C2 (Table
2). Both JK13 and JK5 recognized an epitope(s) located be-
tween amino acids 343 and 374.
Fine mapping of the T-cell epitopes with synthetic peptides.
To further define the T-cell epitopes mapped by recombinant
VV, overlapping peptides were synthesized. JK15, a DEN3
serotype-specific clone, recognized the region of NS3 between
amino acids 234 and 283. DEN3 unique amino acids within this
recognition region were used to predict the location of the
minimal JK15 epitope. Amino acid sequences for the four
serotypes of dengue virus were aligned between amino acids
234 and 283 and compared. As shown in Fig. 2A, two DEN3
unique amino acids (M at position 236 and T at position 248)
were found within this 49-amino-acid sequence. We then
tested peptides containing the second unique amino acid. Two
peptides, 15a and 15b, which overlapped each other by five
amino acids and which both contained this DEN3 unique
amino acid were synthesized (Table 3). JK15 lysed target cells
coated with peptide 15a but not with peptide 15b (Table 3),
indicating that the epitope of JK15 is located between amino
acids 239 and 253. The data obtained with both VV recombi-
nants (Table 2) and peptides (Table 3) indicated that the JK15
epitope contained the unique amino acid at position 248 but
not the one at position 236.
To further delineate the core epitope of JK15, an additional
nine peptides, which were further deleted at either the C ter-
minus or the N terminus, were synthesized. JK15 T cells lysed
homologous target B cells sensitized with peptides 15c, 15d,
15e, 15g, and 15h but not targets sensitized with 15f, 15i, or 15j
(Table 3). These results indicate that the sequence, IRYQT-
TATK, located between amino acids 241 and 249 is the mini-
mal unit required for JK15 recognition.
JK44, a DEN1-, DEN2-, and DEN3-cross-reactive clone,
recognizes the region between amino acids 194 and 214 on
TABLE 2. Recognition of recombinant VV by CD41 CD82
T-cell clones
Clone VV aaa
% Specific 51Cr releaseb
Expt 1 Expt 2 Expt 3 Expt 4 Expt 5
JK15 VVD3-NS3 1–618 47 17 45 — —
VVD3-2 1–548 — 34 32 — —
VVD3-3 1–283 32 64 34 — —
VVD3-5 1–245 — — 0 — —
VVD3-1 1–214 8 — 2 — —
VV 4 5 6 — —
JK44 VVD3-NS3 1–618 — — — 87 —
VVD3-2 1–548 70 78 — — —
VVD3-3 1–283 67 55 — — —
VVD3-5 1–245 54 58 — — —
VVD3-1 1–214 — 66 77 86 59
VVD3-10 1–205 — — — — 4
VVD3-9 1–176 — — — 1 3
VVD3-7 1–133 — — 1 — —
VVD3-4 1–83 — 2 0 — —
VVD3-C1 447–618 9 5 — — —
VV 2 2 6 2 0
JK13 VVD3-NS3 1–618 29 64 — — —
VVD3-2 1–548 27 56 — — —
VVD3-6 1–374 — 78 25 49 —
VVD3-11 1–354 — — — 16 —
VVD3-8 1–340 — — 5 21 —
VVD3-3 1–283 3 — — — —
VVD3-5 1–245 — — 0 — —
VVD3-1 1–214 8 — — 19 —
VVD3-C1 447–618 — 10 — — —
VV 0 7 1 11 —
JK5 VVD3-NS3 1–618 67 65 — — —
VVD3-2 1–548 33 41 — — —
VVD3-6 1–374 — 49 56 36 —
VVD3-11 1–354 — — — 6 —
VVD3-8 1–340 — — 9 — —
VVD3-3 1–283 0 5 — — —
VVD3-5 1–245 — — 7 — —
VVD3-C1 447–618 — 8 — — —
VVD3-C2 412–618 — 4 — — —
VV 6 8 5 1 —
a Amino acid (aa) regions on NS3 expressed by the various VV recombinants.
b Significant levels of lysis are underlined. Experiments not done are indicated
by dashes. The assay time was 4 h for all experiments. Effector/target ratios were
18, 6, and 20 for experiments 1, 2, and 3 with JK15, respectively; 3, 20, 4, and 15
for experiments 1, 2, 3, and 4 with JK13, respectively; 5, 20, 12, and 7 for
experiments 1, 2, 3, and 4 with JK5, respectively; and 13, 13, 20, 10, and 11 for
experiments 1, 2, 3, 4, and 5 with JK44, respectively.
FIG. 2. Alignment of the amino acid sequences of the four dengue virus
serotypes and WNV within the T-cell recognition regions mapped by truncated
NS3 fragments expressed by recombinant VV. Sequences are from references 31
(for DEN3 [H87 strain]), 10 (for DEN1 [Singapore strain]), 18 (for DEN2 [NGC
strain]), 29 (for DEN4 [814669 strain]), and 2 (for WNV). The location of the
region on DEN3 NS3 is indicated by numbers at the N and C termini of each
amino acid sequence. Identical amino acids are indicated by dashes. Asterisks
represent DEN3 unique amino acids. The circles represent amino acids common
in DEN1, DEN2, and DEN3. The arrowhead represents an amino acid common
to DEN1, DEN3, and WNV. Arrows represent the truncation sites of the indi-
cated NS3 fragments expressed by recombinant VV.













NS3. When the amino acid sequences for the four serotypes of
dengue virus were aligned (Fig. 2B), three positions with
amino acids that were common to DEN1, -2, and -3 but not
DEN4 were found. Since JK44 recognized the D3-1 fragment
but not the D3-10 fragment, two peptides were synthesized in
this region. The 44a peptide contained amino acids 184 to 198,
whereas the 44b peptide contained amino acids 201 to 215 and
included three amino acids common to DEN1, DEN2, and
DEN3, located at positions 204, 207, and 213. These peptides
were tested in CTL assays. JK44 recognized peptide 44b but
not peptide 44a (Table 3). To determine the minimum NS3
sequence required for JK44 recognition, we synthesized an
additional seven peptides (44c, 44d, 44e, 44f, 44g, 44h, and
44i), which were further deleted at either the C terminus or the
N terminus (Table 3). The JK44 clone lysed targets coated with
peptide 44e, 44f, or 44h but did not lyse targets coated with
peptide 44c, 44d, 44g, or 44i. Thus, the smallest peptide rec-
ognized by JK44 was determined to be the 10-amino-acid se-
quence, RKYLPAIVRE, located between amino acids 202 and
211 on the NS3 protein.
To define the JK13 and JK5 recognition regions located by
the recombinant VV, a set of six 15-mer peptides, which over-
lapped each other by five amino acids and spanned the region
from amino acids 333 to 372 (between D3-8 and D3-6) (Table
2), were synthesized and tested (Table 4). Both JK5 and JK13
lysed target cells coated with peptide 13-5d but did not lyse
targets coated with the other five peptides (Table 4). Thus, the
peptide 13-5d contains the epitope for both JK5 and JK13.
These results are consistent with those obtained with recom-
binant VVD3-11. The protein expressed by D3-11 was trun-
cated in the center of peptide 13-5d and was therefore not
recognized by either JK13 or JK5 (Table 2). To determine the
minimum sequence required for T-cell recognition by JK13
and JK5, six additional peptides (13-5g, 13-5h, 13-5i, 13-5j,
13-5k, and 13-5l), which were further deleted at either the C
terminus or the N terminus, were synthesized (Table 4). JK13
lysed target cells coated with peptides 13-5g and 13-5i at a
concentration of 2.5 mg/ml but did not lyse targets coated with
peptide 13-5h, 13-5j, 13-5k, or 13-5l at the same concentration,
indicating that the core epitope sequence recognized by JK13
is WITDFVGKTVW. However, at a higher peptide concen-
tration (25 mg/ml), JK13 also lysed targets coated with peptides
13-5h and 13-5k (Table 4).
JK5 recognized peptide 13-5g at a concentration of 0.25
mg/ml but recognized peptide 13-5i only at a higher concen-
tration (25 mg/ml). However, JK5 did not recognize peptides
13-5h, 13-5j, 13-5k, or 13-5l even at a concentration of 25 mg/ml
(Table 4). The core epitope sequence recognized by JK5 is
WITDFVGKTVW. Although the core sequence recognized by
JK5 was identical to that recognized by JK13, JK5 recognized
the core sequence only at concentrations that were 10 times
higher than those required for recognition by JK13. JK13 also
recognized peptides 13-5h and 13-5k at a concentration of 25
mg/ml, but JK5 did not. Both clones recognized the longer
peptide (13-5d) at concentrations as low as 0.025 mg/ml.
A single DEN3 unique amino acid was identified at position
356 in NS3 (position 6 in the core sequence). However, no
amino acid common to DEN1, DEN3, and WNV was found
(Fig. 2C). With the exception of DEN1, all of the dengue virus
strains used for the sequence comparisons were the same as
those used to test the virus specificity of the T-cell clones.
Because the published sequence of DEN1 (Singapore strain)
(10) was used for the amino acid sequence comparison, but
DEN1 (Hawaii strain) was used in the CTL assays, the epitope
region of the DEN1 (Hawaii strain) was PCR amplified,
cloned, and sequenced as described in Materials and Methods.






% Specific 51Cr releasea at concn (mg/ml) of:
2.5 3 100 2.5 3 1021 2.5 3 1022
JK15 1 15a 239–253 LPIRYQTTATKSEHT 54 52 36
15b 244–258 QTTATKSEHTGREIV 0 0 0
2 15a 239–253 LPIRYQTTATKSEHT 59 52 —
15c 239–251 LPIRYQTTATKSE 52 51 —
15d 239–249 LPIRYQTTATK 32 7 —
15e 241–253 IRYQTTATKSEHT 50 46 —
15f 243–253 YQTTATKSEHT 10 2 1
3 15a 239–253 LPIRYQTTATKSEHT 66 64 54
15g 241–250 IRYQTTATKS 58 26 5
15h 241–249 IRYQTTATKb 55 19 9
15i 242–250 RYQTTATKS 9 2 2
15j 242–249 RYQTTATK 5 3 3
JK44 1 44a 184–198 FKKRNLTIMDLHPGS 4 5 5
44b 201–215 TRKYLPAIVREAIKR 49 12 3
2 44b 201–215 TRKYLPAIVREAIKR 20 2 2
44c 203–215 KYLPAIVREAIKR 5 1 1
44d 205–215 LPAIVREAIKR 1 1 0
44e 201–213 TRKYLPAIVREAI 23 15 2
44f 201–211 TRKYLPAIVRE 37 28 6
3 44f 201–211 TRKYLPAIVRE 30 26 15
44g 201–210 TRKYLPAIVR 8 1 0
44h 202–211 RKYLPAIVREb 26 20 10
44i 202–210 RKYLPAIVR 8 1 0
a Effector/target ratios for JK15 were 10 for experiment 1, 8 for experiment 2, and 12 for experiment 3; for JK44, effector/target ratios were 10 for experiments 1 and
3 and 12 for experiment 2. Specific lysis values for the negative control (no peptide) were 7% in experiment 1 and 0% in experiments 2 and 3 with JK15 and 6% in
experiment 1 and 0% in experiments 2 and 3 with JK44. DEN3 antigen was also used in experiment 1 as a positive control, and the specific lysis values were 38% for
JK15 and 71% for JK44. Dashes indicate experiments not done. Values representing significant levels of lysis are underlined.
b The smallest core sequence recognized by the indicated clone.













The sequence of the DEN1 (Hawaii strain) between amino
acids 348 and 365 was identical to that of DEN1 (Singapore
strain).
To confirm that JK5 recognizes the core sequences of the
dengue virus serotypes with which it cross-reacts and to deter-
mine which amino acid residues are critical for recognition by
JK5 and JK13, an additional six 11-mer peptides (13-5i-D1,
13-5i-D2, 13-5i-D2K, 13-5i-D4, 13-5i-D4Q, and 13-5i-WNV)
were synthesized. 13-5i-D1, 13-5i-D2, 13-5i-D4, and 13-5i-
WNV represent the core sequences for DEN1, DEN2, DEN4,
and WNV, respectively. 13-5i-D2K and 13-5i-D4Q were mu-
tated at positions 352 and 355, so that they matched the se-
quence in DEN3 except at position 356 (Fig. 3). Consistent
with its serotype specificity, JK13 recognized 13-5i but not any
of the other six peptides. JK5 recognized peptides 13-5i, 13-
5i-D1, and 13-5-WNV but not 13-5i-D2, 13-5i-D2K, 13-5i-D4,
or 13-5i-D4Q (Fig. 3). Thus, JK5 recognizes the core se-
quences of each of the viruses with which it cross-reacts,
whereas JK13, a DEN3-specific clone, recognizes only the
DEN3 core sequence. The amino acid at position 356 (position
6 in the core epitope) is critical for recognition, since amino
acid substitutions at that position (V to K in DEN2 and V to Q
in DEN4) abolished recognition. The peptide concentration
required for JK5 recognition of the DEN1 epitope was similar
to that required for recognition of the DEN3 core sequence
(Table 4). However, a fourfold-higher concentration of pep-
tide 13-5-WNV than of peptide 13-5i was required for recog-
nition by JK5 (data not shown), suggesting that JK5 has a lower
affinity for the WNV sequence.
Within the core sequence for JK13, there is a single substi-
tution (V to P) at position 356 (position 6 in the core sequence)
in the DEN1 sequence. This mutation is sufficient to abolish
JK13 recognition. Two substitutions are present within the
core sequences of DEN2 and DEN4. To determine which
amino acid substitution abolished JK13 recognition, additional
peptides were synthesized. Since the 13-mer peptide 13-5g and
the 15-mer peptide 13-5d showed higher activity than the 11-
mer core sequence with both the JK13 and JK15 clones (Table
4), the 15-mer peptide was used in this study to ensure good
levels of activity. Peptides 13-5d-D1, 13-5d-D2, and 13-5d-D4
contained the core sequences for DEN1, DEN2, and DEN4,
respectively. Peptides 13-5d-D2K, 13-5d-D2V, 13-5d-D4Y, and
13-5d-D4Q all contained a substitution in the N-terminal
flanking region from H to N at position 349 in DEN2 and from
FD to NE at positions 349 and 350 in DEN4, and thus this
region was identical to the DEN3 sequence. Each of these four
peptides also contained a single substitution within the core
FIG. 3. Analysis of the cytotoxic activities of single residue substitutions
within the JK13/JK5 epitope. The sequences of the peptides 13-5i, 13-5i-D1,
13-5i-D2, 13-5i-D4, 13-5i-WNV, 13-5d, 13-5d-D1, 13-5d-D2, and 13-5d-D4 cor-
responded to those present in each serotype of dengue virus and WNV. Peptides
13-5i-D2K, 13-5i-D4Q, 13-5d-D2K, 13-5d-D2V, 13-5d-D4Y, and 13-5d-D4Q
contained a single amino acid substitution compared with the sequence in DEN3.
The results from T-cell cytotoxic assays are indicated as positive or negative.1/2
indicates that although JK5 did not recognize peptide 13-5i-WNV at the same
concentration as the other peptides, it did recognize this peptide at a fourfold-
higher concentration. The conditions used for the CTL assay are the same as
those described in Table 4, footnote a.






% Specific 51Cr releasea at concn (mg/ml) of:
2.5 3 101 2.5 3 100 2.5 3 1021 2.5 3 1022
JK13 JK5 JK13 JK5 JK13 JK5 JK13 JK5
1 13-5a 333–347 IQDEERDIPERSWNS 5 6 1 1 1 1 — 0
13-5b 338–352 RDIPERSWNSGNEWI 0 4 1 2 2 0 — 2
13-5c 343–357 RSWNSGNEWITDFVG 5 5 3 1 2 1 — 2
13-5d 348–362 GNEWITDFVGKTVWF 66 84 66 78 46 64 34 51
13-5e 353–367 TDFVGKTVWFVPSIK 14 15 4 0 0 0 — 0
13-5f 358–372 KTVWTVPSIKAGNVI 8 12 1 0 0 0 0 0
2 13-5d 348–362 GNEWITDFVGKTVWF — — 83 79 82 74 71 63
13-5g 350–362 EWITDFVGKTVWF — — 66 60 55 48 14 6
3 13-5g 350–362 EWITDFVGKTVWF 69 69 52 65 25 31 3 2
13-5h 348–360 GNEWITDFVGKTV 54 10 19 1 0 0 0 0
13-5i 351–361 WITDFVGKTVWb 62 57 41 1 10 0 0 0
13-5j 352–361 ITDFVGKTVW 11 2 1 1 0 0 0 0
13-5k 351–360 WITDFVGKTV 38 1 5 0 0 0 0 0
13-5l 352–360 ITDFVGKTV 0 0 0 0 0 0 0 0
a Effector/target ratios were 8 for experiments 1 and 3 and 9 for experiment 2. DEN3 antigen was used in experiment 1 as a positive control, and the specific lysis
values were 47% for JK13 and 48% for JK5. Specific lysis values for the negative control were 0% in experiments 1 and 3 and 2% in experiment 2 with JK13 and 0%
in experiments 1 and 3 and 3% in experiment 2 with JK5. Dashes indicate experiments not done. Values representing significant levels of lysis are underlined.
b Smallest core sequence recognized by JK13 and JK5.













sequence (Fig. 3), and thus each differed by only one amino
acid from the DEN3 sequence. JK13 recognized peptides
13-5d and 13-5d-D2V but not peptides 13-5d-D2, 13-5d-D2K,
13-5d-D4, 13-5d-D4Y, and 13-5d-D4Q. Thus, failure of JK13
to recognize the DEN2 core sequence was observed after the
substitution of V with K at position 6 in the peptide but not
after the conservative substitution of I with V at position 2.
Either of the substitutions in DEN4, at position 5 or 6, was
sufficient to abolish recognition by JK13. Thus, the amino acids
in both positions 5 and 6 are critical for JK13 recognition.
Unfortunately, the stock of JK5 cells was depleted prior to the
testing of this second set of peptides with a single amino acid
substitution.
HLA restriction patterns of the T-cell clones. The HLA
restriction pattern for JK44 was analyzed by using anti-HLA-
DR, anti-HLA-DP, and anti-HLA-DQ MAbs. These MAbs
inhibit the cytotoxic activity of homologous HLA-restricted T
cells in a CTL assay. Only the HLA-DR MAb inhibited lysis of
target cells by JK44, indicating that JK44 is HLA-DR restricted
(data not shown).
To determine the HLA-DR allele restriction element for
JK44 and the restriction patterns for the other three clones,
allogeneic target cells, 3107, 3161, 9038, MS, and VA-9, were
used in CTL assays. The HLA subtype pattern for each of
these target cells was defined (Table 5). Allogeneic target cells
3107, 3161, and VA-9 share HLA-DR15 (DR2) and present
the appropriate T-cell specific peptides, 15a and 13-5d, for
recognition by JK15 and JK13/JK5 T-cell clones, respectively.
Target cells 3107 and VA-9 can also present peptide 44b for
recognition by JK44 (Table 5). Cell lines 9038 and MS, which
share HLA-DPw2 and HLA-DQw1 subtypes with the autolo-
gous target cells, respectively, could not present epitopes rec-
ognized by JK15, JK13, JK5, or JK44 (Table 5). The results
indicate that JK15, JK13, JK5, and JK44 are HLA-DR15 re-
stricted.
Determination of the TCR Vb chain usage for JK13 and
JK5. To determine whether JK13 and JK5 arose from the same
lineage, the Vb chains of each clone were sequenced. Reverse
transcription-PCR was performed on RNA extracted from
JK13 and JK15 T cells by using a specific 39 primer, which is
located in the TCR b-chain constant region, and 1 of 26 59
primers located in the variable region of the TCR b chain. Of
the 26 PCRs performed for JK5, only the one in which a 59
specific primer for the Vb1 variable region was used yielded a
PCR product of the expected size, indicating Vb1 usage by the
TCR of JK5. Only the PCR using the 59 primer specific for the
Vb8.1 variable region produced an appropriate-size PCR
product for JK13, indicating that Vb8.1 is used by the TCR of
JK13.
To obtain the amino acid sequences of the b chains of the
JK5 and JK13 TCRs, the PCR products were sequenced. Fig-
ure 4 shows the junction sequences located between the vari-
able region and the constant region of the b chains for the
JK13 and JK5 TCRs. Although these two sequences are highly
conserved, some divergence was observed within the NDN
region and at the beginning of the Jb1.2 region. These results
indicate that JK13 and JK5 are not from the same lineage and
that two CTL clones with different b chains in their TCRs can
recognize the same epitope.
DISCUSSION
We have characterized four human CD41 T-cell clones de-
rived from a donor who experienced dengue illness following
receipt of a live experimental DEN3 vaccine. Core epitopes for
these clones map to three different sequences, 241-IRYQT-
TATK-249 for a DEN3-specific clone, JK15; 202-RKY-
LPAIVRE-211 for a DEN1-, DEN2-, and DEN3-cross-reac-
tive clone, JK44; and 351-WITDFVGKTVW-361 for both a
DEN3-specific clone, JK13, and a DEN1-, DEN3-, and WNV-
cross-reactive clone, JK5. Although the JK13 and JK5 clones
recognized the same core epitope in DEN3, they varied in virus
specificity and in the efficiency with which they recognized
targets coated with a small peptide. Sequence analysis of the
variable regions of the TCRs of the JK13 and JK5 clones
indicated that these two clones use different b chains. These
studies indicate that a single peptide can induce the response
of T cells that possess different TCRs. The various TCRs may
interact with the same peptide in different ways, and this in-
teraction may play a role in determining the serotype specific-
ity of the clones. In support of this hypothesis, the serotype-
specific T-cell clone, JK13, required a lower concentration of
core peptide than did the serotype cross-reactive T-cell clone,
JK5. Similarly, several CD81 T-cell clones induced by the
lymphocytic choriomeningitis virus NP protein in H-2d mice
recognized the same short peptide sequence, even though
these T-cell clones differed slightly from each other in serotype
specificity and in affinity for this minimal epitope (38). Also,
dengue virus-specific, HLA-B35-restricted, peptide-induced
CD81 human T cells had different affinities for the inducing
FIG. 4. Sequence comparison of JK13 and JK5 TCR Vb chains. The JK13
and JK5 TCR Vb chain regions were PCR amplified and sequenced. The se-
quences of the V-D-J region and the constant region (C) of each TCR are shown.
TABLE 5. Determination of HLA class II restriction of JK15, JK13, JK5, and JK44
Target
HLA class II typea % Specific 51Cr releaseb
DR DP DQ JK15 JK13 JK5 JK44
Autologous 15 (52), 103 W2 W5 (5W1), W6 (5W1) 57 46 74 43
3107 2 W4 W2 64 47 63 23
3161 2 — W2 48 27 62 —
9038 12 W2 W7 0 6 7 5
MS 1,4 W4 W1, W3 0 8 7 4
VA-9 15, 17 — W2, W6 44 52 32 15
a Known HLA loci matching that of the T-cell donor are in boldface. —, locus for which HLA type is not known.
b Effector/target ratios were 10 for JK15 and JK5 and 5 for JK44 and JK13. Peptide 15a (0.25 mg/ml) and peptide 44b (2.5 mg/ml) were used to coat target cells for
lysis by JK15 and JK44, respectively. Peptide 13-5d (0.25 mg/ml) was used to coat target cells for lysis by both JK13 and JK5. The CTL assay time was 4 h. Values
representing significant levels of lysis are underlined. The dash indicates that the experiment was not done.













peptide and were heterogeneous in their virus serotype speci-
ficities (27, 39).
The existence of four serotypes of dengue virus provides a
unique opportunity to study how T-cell clones discriminate
some naturally occurring sequences but not others. With this
system, it is possible to analyze both the positions and the
particular amino acids within an epitope that are important for
T-cell recognition. Unlike most other viral immunodominant
proteins which contain one or two T-cell epitopes (6, 15, 37),
our studies (26) have shown that the dengue virus NS3 protein
contains at least four epitopes for this donor. The core epitope
in the DEN3 NS3 sequence recognized by clone JK15 differed
from the one not recognized in the DEN1 sequence by a single
substitution (T to V) at position 8 (Fig. 2A). JK15 also did not
recognize the DEN2 or DEN4 sequence. The DEN4 sequence
contained two substitutions, the same T-to-V change at posi-
tion 8 as in the DEN1 sequence and an additional substitution,
from T to P, at position 6. The DEN2 sequence contained
three substitutions in this region, T to P at position 6, T to I at
position 8, and K to R at position 9. The amino acid substitu-
tion at position 9 of the DEN2 sequence is conservative, but
the substitutions at positions 6 and 8 are not. This result sug-
gests that the amino acid at position 8 is critical for recognition
by JK15. In addition, the amino acid at position 6 and possibly
also the one at position 9 may play a role in recognition.
The JK44 clone can tolerate two conservative amino acid
substitutions, one at position 1 in DEN2 (R to K) and one at
position 2 in DEN1 and DEN2 (K to R) (Fig. 2B). However,
two additional substitutions in DEN4, Y to I at position 3 and
A to S at position 6, were not tolerated, indicating that the
amino acid in either or both of these positions is important for
T-cell recognition.
Although JK13 and JK5 recognize the same minimal core
sequence in DEN3, JK5 also recognizes the core sequences of
DEN1 and WNV. Since this epitope is presented by the same
HLA-DR15 molecule to both clones, the amino acid variations
within the core sequence among the DEN1, DEN3, and WNV
sequences would not be expected to be important for HLA
recognition. The substitution of P for V at position 6 of the
core sequence generated a peptide which was not recognized
by JK13 but was recognized by JK5, indicating that the amino
acid at position 6 is involved in the epitope-TCR interaction.
Substitution of K for V or Q for V at position 6 of the core
sequence was not tolerated by either JK13 or JK5, and substi-
tution of Y for F at position 5 was not tolerated by JK13,
indicating that while position 6 is critical for both JK13 and
JK5 recognition, position 5 may also be important for JK13
recognition. The interaction of the TCR with a peptide bound
to an HLA molecule determines the serotype specificity of
CD41 CTL clones. The amino acids within the peptide that are
critical for HLA-DR15 binding have not been well defined, as
discussed below. The data obtained with the JK13 and JK5
clones suggest that the site on the TCR that reacts with the
HLA-bound peptide is less restrictive in the JK5 clone than in
the JK13 clone. None of the peptides with substitutions at
position 6 could be recognized by JK13, but JK5 could recog-
nize peptides in which position 6 was substituted by another
nonpolar hydrophobic amino acid (Fig. 3). This would explain
the unusual cross-reactivity pattern of the JK5 clone. The
amino acid at position 6 of this epitope may be critical for
recognition by the CTL clones, or alternatively, it may indi-
rectly affect CTL binding by altering the way in which the
critical residues for recognition are exposed on the HLA-
DR15 molecule (37).
Since the amino acid sequence homology among the four
serotypes of dengue virus is fairly high (67 to 75%) (10), one
would expect the epitopes of serotype-cross-reactive clones to
be located in regions of highly conserved sequence and, if they
are not, that these clones would be more tolerant of substitu-
tions than the serotype-specific clones. A previously described
core epitope, 255-EIVDLMCHAT-264, for the HLA-DPw2-
restricted, four-serotype-cross-reactive clone JK34 mapped to
a completely conserved region on the dengue virus NS3 pro-
tein. However, a conservative substitution of V for L at posi-
tion 5 of this core sequence in WNV abolished T-cell recog-
nition (20). On the other hand, two HLA-DR15 restricted
clones, JK43 and JK4, which were four serotype and flavivirus
cross-reactive and recognized the same core sequence on NS3
(26), as well as JK44, the three-serotype-cross-reactive clone
defined in this study (Fig. 2), could tolerate conservative amino
acid substitutions in the first two positions of their core se-
quences. Sequence recognition by serotype-specific T cells
would be expected to be very restricted. However, the DEN3-
specific clone, JK13, tolerated a conservative amino acid sub-
stitution from I to V at position 2 of the core sequence (Fig. 3).
Similarly, the first two amino acids of the core sequence of an
HLA-DR2-restricted T-cell epitope from Mycobacterium lep-
rae could be replaced by almost any other amino acid and still
be recognized (1). These results suggest that the core se-
quences recognized by both HLA-DR15-restricted, dengue vi-
rus serotype-specific and serotype-cross-reactive clones do not
differ markedly in their sequence conservation among the four
dengue virus serotypes. Also, both serotype-specific and sero-
type-cross-reactive clones could tolerate conservative amino
acid substitutions at one of the first two positions. The serotype
cross-reactive T-cell clone, JK5, could also tolerate some but
not all amino acid substitutions at positions 4 (E to D), 5 (Y to
F), and 6 (P or I to V) (Fig. 3).
Naturally processed class II peptides usually contain 13 to 25
amino acids (8, 34). Studies of these peptides after deletion of
amino acids from both the C and N termini have shown that
the minimal length of an active class II peptide is about 9 to 10
amino acids (17). The lengths of the core epitopes for JK15,
JK13/JK5, and JK44 were determined to be 9, 11, and 10
amino acids, respectively. The core sequences for two addi-
tional dengue virus-cross-reactive clones, JK43/JK4 and JK34,
were also shown to be 9 and 10 amino acids in length, respec-
tively (20, 26). These results are consistent with other studies of
T-cell class II epitopes in human viruses, in which core se-
quences of CD41 epitopes from hepatitis B virus and human
immunodeficiency virus type 1 were found to be 10 and 12
amino acids in length, respectively (6, 15). Studies with HLA-
eluted peptides have shown that deletion of two amino acids
from either the N terminus or the C terminus of an 18-mer or
17-mer peptide did not decrease the peptide’s ability to bind to
class II molecules, but further deletions did lead to some re-
duction in binding, although activity could still be demon-
strated for peptides as short as nine amino acids (17). In our
study, the longer 15-mer peptides, such as 15a and 13-5d,
induced a higher level of lysis than did the shorter core se-
quences, 15h and 13-5i, and the T-cell clones required 100- to
1,000-fold less of a 15-mer peptide than of the shorter core
sequences for recognition. This finding suggests that the flank-
ing sequences assist in the presentation of the peptide.
The four T-cell clones used in this study are HLA-DR15
restricted. HLA-DR2 was recently reclassified as HLA-DR15
and HLA-DR16 (3). Two consensus binding motifs for HLA-
DR2 were previously proposed on the basis of the sequences of
endogenous peptides eluted from HLA-DR2a/DR2b mole-
cules (Fig. 5). An i 1 10th motif was observed in 7 of 10
peptides, where i represents I, L, or V and 1 10 indicates that
a positively charged amino acid (H, K, or R) is present at













position 10 (8). In contrast, another study proposed a VK 1 4
motif for HLA-DR2 (genotype DRb1*1502) peptides (16).
Because naturally processed, HLA class II-restricted peptides
usually contain more amino acids than are required for HLA
binding and T-cell recognition, motifs predicted on the basis of
amino acid conservation in eluted peptides may not accurately
predict the region of the epitopes critical for HLA binding
since the minimal epitope region within these peptides cannot
be identified. The DR15-restricted dengue virus NS3 minimal
epitope sequences that we defined in this study as well as an
additional DR15-restricted dengue virus NS3 epitope, 146-
VIGLYGNGV-154, reported previously (26) do not appear to
fit either of the two proposed motifs (Fig. 5). When the core
sequence for JK15 (Fig. 2A) is extended two residues at the
N-terminal end, it does fit the i 1 10th motif (i 5 L and K at
position 10), but these two additional amino acids (L and P) do
not appear to be essential for the binding of this peptide to the
HLA molecule (Table 3, peptides 15a and 15e). These data
suggest that an L in the i position may not be important for
peptide recognition. Comparison of the minimal recognition
sequences defined on the dengue virus NS3 protein indicates
that a positive amino acid, K or R, is located at position 8 or 9
(Fig. 5). A DR2-restricted epitope, LQAAPALDKL, previ-
ously defined for M. leprae also contains a K in position 9.
Although the first two amino acids or the last amino acid in the
M. leprae core sequence could be replaced with almost any
other amino acid without affecting recognition by T cells, the
other amino acids, including K at position 9, were essential for
recognition (1). Since the majority of the peptides that bind to
the HLA-DR2 molecule have a positively charged amino acid
at or near the C terminus of the minimal epitope sequence, it
is likely that this residue is involved in the interaction with the
HLA-DR2 molecule. However, since HLA-DR2 has now been
subdivided into HLA-DR15 and HLA-DR16, and within the
HLA-DR2 population HLA-DR15 is the minority isotype (8),
further studies are required to define and compare the motifs
critical for HLA-DR15 and HLA-DR16 molecule binding.
This study provides additional data about the human T-cell
response to dengue virus infection that will be important for
future analyses of T-cell responses in patients with DHF. A
precise understanding of human immune responses to dengue
virus is also necessary as an aid to the development of a safe
and effective vaccine which can simultaneously induce long-
lasting protective immunity to the four serotypes of dengue
viruses.
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